REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 21st, 2004 • Incara Pharmaceuticals Corp • Pharmaceutical preparations • New York
This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 19th day of April, 2004 by and among INCARA PHARMACEUTICALS CORPORATION, a Delaware corporation (the “Company”), the “Investors” named in that certain Purchase Agreement, dated April 19, 2004, by and among the Company and the Investors (the “Purchase Agreement”), and SCO Securities LLC, a Delaware limited liability company (the “Placement Agent”). Capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Purchase Agreement.
PURCHASE AGREEMENTPurchase Agreement • April 21st, 2004 • Incara Pharmaceuticals Corp • Pharmaceutical preparations • New York
THIS PURCHASE AGREEMENT (“Agreement”) is made as of this 19th day of April, 2004 by and among INCARA PHARMACEUTICALS CORPORATION, a Delaware corporation (the “Company”), and the Investors set forth on Schedule I affixed hereto, as such Schedule may be amended from time to time in accordance with the terms of this Agreement (each an “Investor” and collectively the “Investors”).
ContractIncara Pharmaceuticals Corp • April 21st, 2004 • Pharmaceutical preparations • New York
THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR EXEMPTION FROM REGISTRATION UNDER THE FOREGOING LAWS.
AGREEMENT AND AMENDMENT NO. 1 TO THE DEBENTURE AND WARRANT PURCHASE AGREEMENTAgreement • April 21st, 2004 • Incara Pharmaceuticals Corp • Pharmaceutical preparations • New York
This AGREEMENT AND AMENDMENT NO. 1 TO THE DEBENTURE AND WARRANT PURCHASE AGREEMENT (this “Agreement”), is made as of April 19, 2004, by and among Incara Pharmaceuticals Corporation (f/k/a Incara, Inc.), a Delaware corporation (the “Company”) and successor-by-merger to Incara Pharmaceuticals Corporation (the “Former Parent”), and Goodnow Capital, L.L.C., a Delaware limited liability company and successor-by-merger to Goodnow Capital, Inc. (the “Investor”).
